STAAR Surgical Company (STAA)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.26 | 5.99 | 5.80 | 5.84 | 5.62 | 6.11 | 6.05 | 6.65 | 6.03 | 6.55 | 6.37 | 6.65 | 5.56 | 5.64 | 5.94 | 6.19 | 5.25 | 5.79 | 5.78 | 5.75 |
| Quick ratio | 1,235.41 | 3.56 | 3.55 | 3.91 | 3.39 | 3.31 | 3.54 | 4.33 | 4.09 | 4.66 | 6.12 | 4.69 | 4.09 | 4.19 | 4.14 | 4.49 | 3.70 | 3.79 | 3.68 | 3.71 |
| Cash ratio | 1,235.41 | 3.56 | 3.55 | 3.91 | 3.39 | 3.31 | 3.54 | 4.33 | 4.09 | 4.66 | 6.12 | 4.69 | 4.09 | 4.19 | 4.14 | 4.49 | 3.70 | 3.79 | 3.68 | 3.71 |
The current ratio of STAAR Surgical Company has been consistently strong over the analyzed periods, ranging from 5.25 to 6.65. This indicates that the company has more than enough current assets to cover its current liabilities, reflecting a healthy liquidity position.
The quick ratio, which provides a more stringent measure by excluding inventory from current assets, also demonstrates a robust liquidity position for STAAR Surgical Company. Although there was a significant anomaly in the quick ratio for December 31, 2024, likely due to data reporting errors, the ratio generally ranged from 3.31 to 6.12, indicating the company's ability to meet its short-term obligations without relying on selling inventory.
Similarly, the cash ratio, which represents the ability to cover current liabilities with cash and cash equivalents, remained strong for STAAR Surgical Company. There seems to be the same anomaly for December 31, 2024, where the value is unusually high, likely due to data issues. However, the ratio generally ranged between 3.31 and 6.12, demonstrating the company's capability to settle its short-term debts with cash on hand.
Overall, based on the liquidity ratios analysis, STAAR Surgical Company appears to have a robust liquidity position, with ample current assets to meet short-term obligations efficiently and effectively.
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 0.21 | 203.01 | 207.40 | 200.83 | 183.80 | 165.57 | 138.02 | 161.01 | 144.55 | 119.73 | 113.39 | 124.34 | 121.64 | 121.75 | 116.89 | 132.41 | 146.58 | 153.14 | 157.81 | 159.27 |
STAAR Surgical Company's cash conversion cycle has shown fluctuations over the years. In March 2020, the company took 159.27 days to convert its investments in inventory and receivables into cash. This cycle decreased steadily to 116.89 days by June 2021, reflecting improvements in managing inventory and collecting receivables more efficiently.
However, the cycle slightly increased to 144.55 days by December 2022 before reaching its peak of 207.40 days in June 2024. This spike indicates potential issues in managing inventory levels and accounts receivable, causing a delay in the cash conversion process.
By December 2024, the cash conversion cycle drastically dropped to just 0.21 days. Such a sharp decline may indicate a significant improvement in managing working capital and converting investments into cash quickly.
Overall, STAAR Surgical Company has experienced fluctuations in its cash conversion cycle, with periods of both efficiency and inefficiency in converting operating investments into cash. Monitoring and analyzing these cycles are crucial for optimizing working capital management and overall financial performance.